Dergiler / Turkish Journal of Medical Sciences / 2020 / Cilt: 50 - Sayı: 3

Antiviral treatment of COVID-19

Sayfa
611–619
Yayın Tarihi
2022-11-04
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as theyhave recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other humaninfections.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Currently, there is not any specific effective antiviral treatment for COVID-19.
📊
Temel Bulgular & Veri:Although most of the COVID-19 patients havemild or moderate courses, up to 5%–10% can have severe, potentially life threatening course, there is an urgent need for effective drugs.Optimized supportive care remains the mainstay of therapy.
💡
Sonuç & Katkı:The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as theyhave recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other humaninfections.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Abstract

Currently, there is not any specific effective antiviral treatment for COVID-19. Although most of the COVID-19 patients havemild or moderate courses, up to 5%–10% can have severe, potentially life threatening course, there is an urgent need for effective drugs.Optimized supportive care remains the mainstay of therapy. There have been more than 300 clinical trials going on, various antiviraland immunomodulating agents are in various stages of evaluation for COVID-19 in those trials and some of them will be publishedin the next couple of months. Despite the urgent need to find an effective antiviral treatment for COVID-19 through randomizedcontrolled studies, certain agents are being used all over the world based on either in-vitro or extrapolated evidence or observationalstudies. The most frequently used agents both in Turkey and all over the world including chloroquine, hydroxychloroquine, lopinavir/ritonavir, favipiravir and remdesivir will be reviewed here .Nitazoxanide and ivermectin were also included in this review as theyhave recently been reported to have an activity against SARS-CoV-2 in vitro and are licensed for the treatment of some other humaninfections.

🔖

Bu Makaleye Atıf Yap

ÜNAL, S., YAVUZ, S. Ş. (2022). Antiviral treatment of COVID-19. Turkish Journal of Medical Sciences, Cilt: 50 - Sayı: 3, 611–619. https://ajindex.com/articles/609737

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (3)

  1. Hoffmann C. Treatment. In: Kamps BS, Hoffmann C, eds. Covid Reference, Edition 2020-2. SteinHauser Verlag; Amedeo, Germany; 2020. Website www.covidreference.com [accessed 12 April 2020]
  2. McCreary EK, Pogue JM. Coronavirus disease 2019 treatment: a review of early and emerging options. Open Forum Infectious Diseases 2020; 7(4): ofaa105. doi: 10.1093/ofid/ofaa105 3. Kalil AC. Treating COVID-19–Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. JAMA 2020. doi: 10.1001/jama.2020.4742 4. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM et al. Clinical practice guidelines by the infectious diseases society of America: 2018 update on diagnosis, treatment, chemoprophylaxis, and institutional outbreak management of seasonal influenzaa. Clinical Infectious Disesases 2019; 68: e1. doi: 10.1093/cid/ciy866 5. Chan KS. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Medical Journal 2003; 9: 399-406
  3. Schrezenmeie E, Dörner T. Mechanisms of action of hydroxychloroquine and chloroquine: implications for rheumatology. Nature Reviews Rheumatology 2020; 16 (3): 155- 166. doi: 10.1038/s41584-020-0372-x 7. Liu J, Cao R, Xu M, Wang X, Zhang H et al. Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro. Cell Discovery 2020. doi: 10.1038/s41421-020-0156-0.15 8. Wang M, Cao R, Zhang L, Yang X, Liu J et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Research 2020; 30: 269- 71. doi: 10.1038/s41422-020-0282-0 9. Lu CC, MY, Chen, Chang YL. Potential therapeutic agents against COVID-19: What we know so far. Journal of the Chinese Medical Association 2020. doi: 10.1097/JCMA.0000000000000318 10. Yao X, Ye F, Zhang Z,Cui C, Huang B et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clinical Infectious Diseases 2020; ciaa237. doi: 10.1093/cid/ciaa237 11. Barlow A, Landolf KM, Barlow B, Yeung SYA, Heavner JJ et al. Review of emerging pharmacotherapy for the reatment of coronavirus disease 2019. Pharmacotherapy 2020. doi: 10.1002/ phar.2398 12. Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.